March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq ... The primary endpoint is the proportion of eyes improving ≥2 steps on Diabetic Retinopathy Severity Scale ("DRSS") from baseline at Week ...

Shares of Kodiak Sciences KOD have skyrocketed 270.7% in the past six months fueled by updates from the developmental program of its lead investigational candidate, tarcocimab. It is a novel anti ...

VETi is an autonomous AI- and machine-learning-enabled headset that engages directly into the eye. Our goal is to commercialize VETi together with Kodiak's emerging portfolio of retinal medicines ...

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical ... Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for ...

So should Kodiak Sciences (NASDAQ:KOD) shareholders be worried about its cash burn? For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund ...

March 10, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today announced that it has completed enrollment in its GLOW2 Phase 3 clinical trial of tarcocimab tedromer in patients with ...

Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth ...